Jurgi Camblong Sells 2,600 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Key Points

• CEO Jurgi Camblong sold 2,600 shares on April 6 at an average price of $4.85 (≈$12,610) under a pre-arranged Rule 10b5‑1 plan to cover tax withholding, leaving him with 3,731,450 shares (a 0.07% reduction).
• SOPHiA GENETICS reported an EPS miss for the quarter—($0.28) versus ($0.20) expected—while revenue of $21.71M slightly beat estimates, and the company shows negative profitability (ROE -50.6%, net margin -44.2%) with analysts projecting about -0.96 EPS for the year.
• Analyst sentiment is mixed (two Buys, one Sell) with a consensus "Hold" and a $7.00 price target; the stock trades near $4.89 with a market cap of ~$334.6M and roughly 31.6% institutional ownership.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CEO Jurgi Camblong sold 2,600 shares of the stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $4.85, for a total value of $12,610.00. Following the transaction, the chief executive officer owned 3,731,450 shares of the company's stock, valued at approximately $18,097,532.50. This trade represents a 0.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Tuesday, April 7th, Jurgi Camblong sold 2,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.86, for a total value of $12,150.00.
• On Thursday, March 19th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.77, for a total value of $21,398.22.

SOPHiA GENETICS Stock Down 0.3%

SOPH stock traded down $0.01 during trading hours on Wednesday, reaching $4.89. 64,929 shares of the stock were exchanged, compared to its average volume of 188,371. The firm's 50-day moving average is $4.78 and its 200-day moving average is $4.68. The company has a market cap of $334.64 million, a price-to-earnings ratio of -9.58 and a beta of 1.04. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84. SOPHiA GENETICS SA has a 12 month low of $2.58 and a 12 month high of $5.70.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). The firm had revenue of $21.71 million for the quarter, compared to the consensus estimate of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%. On average, equities research analysts expect that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Guggenheim increased their target price on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a report on Monday, January 26th. Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Finally, BTIG Research reiterated a "buy" rating and set a $7.00 target price on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $7.00.

Hedge Funds Weigh In On SOPHiA GENETICS

Several hedge funds have recently modified their holdings of SOPH. Savvy Advisors Inc. bought a new position in shares of SOPHiA GENETICS in the 3rd quarter valued at about $48,000. Squarepoint Ops LLC bought a new position in shares of SOPHiA GENETICS in the 3rd quarter valued at about $49,000. Perkins Capital Management Inc. bought a new position in shares of SOPHiA GENETICS in the 4th quarter valued at about $49,000. Quadrature Capital Ltd bought a new position in shares of SOPHiA GENETICS in the 4th quarter valued at about $54,000. Finally, XTX Topco Ltd bought a new position in shares of SOPHiA GENETICS in the 4th quarter valued at about $55,000. Institutional investors own 31.59% of the company's stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.